July 18, 2018
Three MPii projects showcased their evidence-based work at AIDS 2018 in Amsterdam, from July 21 – 27, 2018. Here’s an overview of what was presented: OPTIONS Pre-conference “Insight to Impact: Driving Demand Creation for HIV Prevention.” Oral Abstract Session “Factors influencing initiation, continuation & discontinuation of oral PrEP at selected facilities in South Africa.” Part… Read more »
June 12, 2018
The Global Evaluation of Microbicide Sensitivity (GEMS) project has developed a toolkit focused on HIV drug resistance within PrEP rollout programs. These toolkit materials are designed to help policymakers, health care workers, and laboratory personnel develop and implement drug resistance monitoring programs. New materials will be added, so be sure to visit the GEMS website frequently. PrEP… Read more »
December 20, 2017
At ICASA 2017, OPTIONS presented the poster, “Involving young people in rollout of oral PrEP: The case in Kenya.” In November, the GEMS team presented an oral session on the potential challenges that PrEP implementation may pose to HIV drug resistance emergence at the annual meeting for WHO HIVResNet, a global network advising WHO on… Read more »
December 20, 2017
At ICASA 2017, held 4-9 December in Cote d’Ivoire, OPTIONS and WHO co-hosted a satellite session, titled “Making the case for PrEP for women: What we know and experiences to date.” More than 200 people attended the session, which reviewed current and new evidence about delivering oral PrEP to women, particularly adolescent girls and young… Read more »
December 20, 2017
To foster innovation and problem-solving within oral PrEP delivery, AVAC and LVCT Health, through OPTIONS, created six short documentary videos that offer lessons learned for implementers and policymakers. The “Providing Oral PrEP” videos capture real stories from end users and providers about their experiences with oral PrEP, looking closely at several IPCP demonstration project sites… Read more »
December 20, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Drug resistance testing in Kenya progresses. Drug resistance testing in South Africa planned. Collaboration in Zimbabwe begins. GEMS to offer technical assistance on drug resistance testing. Oral… Read more »
December 20, 2017
CHARISMA supports efforts to: increase women’s agency to safely use ARV-based HIV prevention, to engage male partners in HIV prevention, and to overcome harmful gender norms and reduce intimate partner violence (IPV). Clinic-based intervention continues. Community-based intervention completed in September. CHARISMA pilot evaluation underway and effectiveness study planned. Clinic-based intervention continues. CHARISMA is piloting its… Read more »
December 20, 2017
EMOTION increases uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy. Project VOGUE continues. Project VOGUE continues. To-date, EMOTION has completed the first and second of its four project aims (known as Kalahari 1, 2, and Siyavala). Project VOGUE (EMOTION’s… Read more »
December 20, 2017
POWER develops cost-effective and scalable models for implementation of ARV-based HIV prevention products for women. Cohorts in Cape Town, Johannesburg, and Kisumu enroll more than 200 young women. My PrEP decision support tool ready to launch; additional demand creation tools in development. POWER team meeting convened. Cohorts in Cape Town, Johannesburg, and Kisumu enroll more… Read more »